07.06.2013 Views

Emerging LVAD Technology for the Use - Washington Hospital Center

Emerging LVAD Technology for the Use - Washington Hospital Center

Emerging LVAD Technology for the Use - Washington Hospital Center

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

• FDA approved<br />

Thoratec HeartMate II LVAS<br />

– Bridge to transplant – 2009<br />

– Destination Therapy – 2010<br />

• Clinical Experience<br />

– > 10,000 implants worldwide<br />

– Patients supported ≥ 3 years: 455<br />

– Patients supported ≥ 4 years: 158<br />

– Patients supported ≥ 5 years: 43<br />

– Patients supported ≥ 6 years: 14<br />

0<br />

– Patients supported ≥ 7 years: 2 Months<br />

Percent Survival<br />

100<br />

90<br />

80<br />

70<br />

60<br />

50<br />

40<br />

30<br />

20<br />

10<br />

Implant dates n 30 d 6 Mo 12 mo<br />

a Apr ’08 - Oct ‘10 1496 95% 89% 85%<br />

b Apr ’08 - Aug ‘08 169 96% 90% 85%<br />

c Mar ’07 - Apr ‘08 205 95% 86% 80%<br />

d Mar ’05 - Mar ‘07 281 92% 82% 73%<br />

e Mar ’05 - May ’06 133 89% 75% 68%<br />

a John et al STS 2011<br />

b Starling et al JACC (in press)<br />

d Pagani et al JACC 2009<br />

e Miller et al NEJM 2007<br />

0 6 12<br />

Late Trial c<br />

Post-Trial a<br />

Post-Approval Study b<br />

Early-mid Trial d<br />

Early Trial e

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!